Randomized, Controlled Study Comparing the Efficacy and Safety of Docetaxel (60mg/m2)Maintenance Treatment vs. Best Supportive Care Following First Line Chemotherapy With Different Doses of Docetaxel(75/60mg/m2)in Combination With Cisplatin in Patients With Local Advanced or Metastatic (Stage IIIB/IV)Non-Small Cell Lung Cancer.
Phase of Trial: Phase III
Latest Information Update: 29 Apr 2014
At a glance
- Drugs Docetaxel (Primary) ; Cisplatin
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms TFINE
- Sponsors Sanofi
- 04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
- 01 Aug 2012 Primary endpoint 'Progression-free-survival-duration' has been met.
- 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History